AtriCure (NASDAQ:ATRC) Stock Price Target Raised at JPMorgan Chase & Co.

by · The Markets Daily

AtriCure (NASDAQ:ATRC – Get Free Report) had its price objective upped by analysts at JPMorgan Chase & Co. from $36.00 to $62.00 in a report released on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the medical device company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential downside of 4.20% from the company’s current price.

Several other research analysts have also commented on the company. Weiss Ratings raised AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Freedom Capital downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Needham & Company LLC raised their target price on shares of AtriCure from $64.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and issued a $70.00 target price (up from $60.00) on shares of AtriCure in a report on Wednesday. Finally, Citizens Jmp upped their price target on shares of AtriCure from $52.00 to $68.00 and gave the company a “market outperform” rating in a research report on Wednesday, October 21st. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $60.60.

Read Our Latest Stock Analysis on AtriCure

AtriCure Stock Performance

ATRC traded up $4.31 on Wednesday, reaching $64.72. The company had a trading volume of 712,495 shares, compared to its average volume of 871,546. The stock has a 50-day moving average price of $56.03 and a 200-day moving average price of $38.40. The stock has a market capitalization of $3.29 billion, a PE ratio of 306.12 and a beta of 1.23. AtriCure has a 1 year low of $25.36 and a 1 year high of $65.09. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The medical device company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.23. The business had revenue of $154.45 million during the quarter, compared to the consensus estimate of $151.05 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%. As a group, research analysts forecast that AtriCure will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at AtriCure

In other news, insider Karl S. Dahlquist sold 9,370 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the sale, the insider owned 87,319 shares in the company, valued at $4,269,025.91. This represents a 9.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Regina E. Groves sold 5,313 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $54.22, for a total value of $288,070.86. Following the sale, the director directly owned 34,546 shares of the company’s stock, valued at approximately $1,873,084.12. This represents a 13.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 30,622 shares of company stock worth $1,626,003. 4.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AtriCure

A number of large investors have recently bought and sold shares of the company. Man Group plc purchased a new stake in shares of AtriCure in the second quarter valued at about $684,000. Bank of America Corp DE raised its holdings in AtriCure by 13.7% during the first quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock worth $21,927,000 after purchasing an additional 92,830 shares in the last quarter. WINTON GROUP Ltd purchased a new position in AtriCure during the second quarter worth about $1,002,000. The Manufacturers Life Insurance Company acquired a new stake in AtriCure in the second quarter valued at about $699,000. Finally, Jupiter Topco LLC purchased a new stake in AtriCure in the 2nd quarter valued at approximately $640,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Key Stories Impacting AtriCure

Here are the key news stories impacting AtriCure this week:

  • Positive Sentiment: AtriCure reported Q3 revenue of $154.45 million, above the $151.05 million consensus, and earnings of $0.17 per share, beating estimates. AtriCure beats Q3 earnings and revenue estimates
  • Positive Sentiment: Management forecast 2026 revenue of $606 million to $610 million and adjusted EBITDA of $91 million to $94 million, supporting a constructive growth outlook. The revenue range is close to the cited FactSet estimate of $606.2 million. AtriCure projects 2026 adjusted EBITDA
  • Positive Sentiment: Analyst sentiment improved after the results: Piper Sandler reaffirmed its overweight rating and raised its target to $70 from $60, while Needham raised its target to $70 from $64 and kept a buy rating. BTIG also lifted its target to $70. Analysts boost forecasts after Q3 results BTIG raises AtriCure price target
  • Neutral Sentiment: The company is targeting completion of enrollment in its BoxX-NoAF study by year-end; the milestone may inform future clinical and commercial prospects, but no new results were reported. AtriCure study enrollment and outlook

AtriCure Company Profile

(Get Free Report)

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.

See Also